{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:19:19Z","timestamp":1771514359937,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116161","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T22:14:51Z","timestamp":1768601691000},"page":"116161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial"],"prefix":"10.1016","volume":"172","author":[{"given":"Junfeng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.intimp.2026.116161_bb0005","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/jama.2022.5270","article-title":"Psoriasis","volume":"327","author":"Walter","year":"2022","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.intimp.2026.116161_bb0010","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.intimp.2026.116161_bb0015","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2026.116161_bb0020","first-page":"562","article-title":"Psoriasis: recognition and management strategies","volume":"108","author":"Garner","year":"2023","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.intimp.2026.116161_bb0025","doi-asserted-by":"crossref","unstructured":"F. Poizeau, S. Leducq, L. Fardet, M. Beylot-Barry, G. Chaby, M. Chastagner, F. Corgibet, L. Gouillon, N. Jouan, D. Jullien, A. Acher, F. Amatore, J.M. Amici, H. Aubert, F. Aubin, N. Beneton, D. Bouilly, A.C. Bursztejn, C. Buzenet, M. Chamaillard-Pujol, J. Charles, A.C. Cottencin-Charriere, B. Duval Modeste, A. Fauconneau, A.C. Fougerousse, C. Girard, C. Goujon, A. Khemis, Y. Le Ru, C. Lepelley-Dupont, E. Mahe, X. Marcellin, C. Nicolas, V. Pallure, J. Parier, N. Quiles, P.E. Stoebner, M. Tauber, A. Vermersch, M. Viguier, A.P. Villani, O. Chosidow, B. Guillot, G. Psoriasis Research, D. the Centre of Evidence of the French Society of, Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithm, Ann Dermatol Venereol 151(3) (2024) 103287.","DOI":"10.1016\/j.annder.2024.103287"},{"issue":"5","key":"10.1016\/j.intimp.2026.116161_bb0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1590\/abd1806-4841.20175603","article-title":"Moderate to severe psoriasis treatment challenges through the era of biological drugs","volume":"92","author":"Vide","year":"2017","journal-title":"An. Bras. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116161_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14041312","article-title":"Therapeutic advancements in psoriasis and psoriatic arthritis","volume":"14","author":"Yi","year":"2025","journal-title":"J. Clin. Med."},{"issue":"17","key":"10.1016\/j.intimp.2026.116161_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 1","key":"10.1016\/j.intimp.2026.116161_bb0045","article-title":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116161_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14890","article-title":"Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice","volume":"33","author":"Zhou","year":"2024","journal-title":"Exp. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116161_bb0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a Meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116161_bb0060","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","article-title":"Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation","volume":"18","author":"Galluzzo","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.116161_bb0065","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/1346-8138.17249","article-title":"Impact of residual skin lesions and previous biologic treatment failure on patient-reported outcomes in patients with psoriasis receiving biologic treatment","volume":"51","author":"Song","year":"2024","journal-title":"J. Dermatol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116161_bb0070","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","article-title":"Vunakizumab: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2026.116161_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2024.09.031","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"92","author":"Yan","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116161_bb0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis","volume":"87","author":"Zhang","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116161_bb0085","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13555-024-01159-3","article-title":"Unmet needs and treatment preference of systemic treatments for moderate-to-severe psoriasis from the perspectives of patients and dermatologists in China","volume":"14","author":"Kuang","year":"2024","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"10","key":"10.1016\/j.intimp.2026.116161_bb0090","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s13555-024-01264-3","article-title":"Efficacy of Brodalumab in patients with psoriasis and risk factors for treatment failure: a review of post hoc analyses","volume":"14","author":"Lebwohl","year":"2024","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"4","key":"10.1016\/j.intimp.2026.116161_bb0095","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s13555-020-00411-w","article-title":"Brodalumab to the rescue: efficacy and safety of Brodalumab in patients with psoriasis and prior exposure or inadequate response to biologics","volume":"10","author":"Menter","year":"2020","journal-title":"Dermatol. Ther. (Heidelb.)"},{"issue":"3","key":"10.1016\/j.intimp.2026.116161_bb0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis","volume":"38","author":"Hu","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.intimp.2026.116161_bb0105","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials","volume":"180","author":"Langley","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116161_bb0110","first-page":"123","article-title":"Efficacy of Brodalumab and Guselkumab in patients with moderate-to-severe plaque psoriasis who are inadequate responders to Ustekinumab: a matching adjusted indirect comparison","volume":"11","author":"Hampton","year":"2021","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"10.1016\/j.intimp.2026.116161_bb0115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","article-title":"Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed","volume":"81","author":"Kimmel","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116161_bb0120","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaad.2020.11.013","article-title":"Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors","volume":"84","author":"Yeung","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116161_bb0125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1080\/09546634.2020.1716932","article-title":"Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study","volume":"32","author":"Kromer","year":"2021","journal-title":"J. Dermatolog. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2026.116161_bb0130","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15106","article-title":"Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis","volume":"34","author":"Loft","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116161_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjd.18623","article-title":"Secukinumab for patients failing previous tumour necrosis factor-alpha inhibitor therapy: results of a randomized open-label study (SIGNATURE)","volume":"183","author":"Warren","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116161_bb0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-016-0246-9","article-title":"Efficacy and safety of switching to Ixekizumab in etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3)","volume":"18","author":"Blauvelt","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116161_bb0145","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/jamadermatol.2023.5439","article-title":"Patient-reported outcome measures for health-related quality of life in patients with psoriasis: a systematic review","volume":"160","author":"Perez-Chada","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116161_bb0150","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1365-2133.2011.10469.x","article-title":"Patient-reported outcomes in psoriasis research and practice","volume":"165","author":"Otuki","year":"2011","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116161_bb0155","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1080\/09546634.2022.2116266","article-title":"Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting","volume":"33","author":"Strober","year":"2022","journal-title":"J. Dermatolog. Treat."},{"issue":"2","key":"10.1016\/j.intimp.2026.116161_bb0160","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jdv.16632","article-title":"Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results","volume":"35","author":"Augustin","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:31:20Z","timestamp":1771511480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"alternative-id":["S1567576926000044"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116161","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116161"}}